At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
Lorlatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2, MULTI-CENTER, OPEN-LABEL, DUAL-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORLATINIB (PF-06463922) MONOTHERAPY IN ALK INHIBITOR-TREATED LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS IN CHINA
In Brief
A Phase 2 clinical trial evaluating Lorlatinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 109 participants across 21 sites.
Detailed Summary
A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer patients in China
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartApr 2019
Primary CompletionAug 2020
Study CompletionOct 2024
TodayJul 2026
First PostedApr 10, 2019
Enrollment StartApr 28, 2019
Primary CompletionAug 10, 2020
Study CompletionOct 21, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.2 years ago
Interventions
Lorlatinibdrug
ALK inhibitor-treated ALK-positive NSCL treatment